PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Trevigen, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2 - When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA
Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2

 

NewswireToday - /newswire/ - Arlington, VA, United States, 2008/03/04 - When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DNA damage caused by oxidative radicals is associated with aging, inflammation, carcinogenesis, Parkinson’s and Alzheimer’s diseases. When exposed to oxidative radicals, 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) is formed and can serve as a sensitive indicator of physiological and environmental damage to DNA. This mouse monoclonal antibody specifically binds to 8-hydroxy-2’-deoxyguanosine within DNA in H2O2-treated cells.

It can be used to detect oxidative damage by ELISA and immunocytochemistry. For optimal outcomes, cells should be grown on a surface that allows for fixation and direct labeling such as sterile chamber slides and coverslips. This antibody is provided as purified immunoglobulin from mouse ascites in 1X PBS containing 0.01% sodium azide.

Sufficient antibody is provided for approximately 50 slides, when a 1:250 dilution is used (Cat# 4354-MC-050). For details, contact Trevigen by phone at 800-873-8443, by email, or visit the website.

About Trevigen
Trevigen (trevigen.com) is a long standing provider of quality kits and reagents for researchers investigating programmed cell death, DNA damage and repair, cell differentiation and angiogenesis. Trevigen recently launched Anti-8-oxo-dG Monoclonal Antibody (Clone 2E2) as part of it DNA Damage product line.

References:
1 Soultanakis RP, Melamede RJ, Bespalov IA, Wallace SS, Beckman KB, Ames BN, Taatjes DJ, Janssen-Heininger YMW. (2000) Flourescence detection of 8-oxoguanine in nuclear and mitochondrial DNA of cultured cells using a recombinant Fab and confocal scanning laser microscopy. Free Rad Biol Med 28:987-998.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Trevigen, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody Clone 2E2

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Anti-8-oxo-dG Monoclonal |
Publisher Contact: Belinda De Leon - Trevigen.com 
1-800-TREVIGEN info[.]trevigen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Trevigen, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Trevigen, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)